Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Sepracor Launches ”My Allergies in America” Web Site, a New Online Resource for Physicians and Nasal Allergy Sufferers

April 22, 2008

Sepracor Inc. (Nasdaq: SEPR) announced today the launch of “My Allergies in America” (www.myallergiesinamerica.com), a comprehensive resource for physicians and consumers based on the two-part, landmark “Allergies in America” survey of adults, adolescents and children with allergic rhinitis. The survey, endorsed by the American College of Allergy, Asthma and Immunology (ACAAI), showed that allergies, which affect about 40 million people in the United States, including up to 40 percent of children1, are linked to quality of life issues.

A complete overview of the entire survey, including executive summaries, downloadable detailed presentations, patient information on allergy management and other resources can be found on the web site.

“Sepracor is pleased to sponsor myallergiesinamerica.com as part of its commitment to the treatment of respiratory diseases,” said Mark H.N. Corrigan, M.D., Executive Vice President of Research and Development at Sepracor. “We believe the web site is a valuable tool that offers important information relative to the experiences and perceptions of nasal allergy sufferers, their caregivers and health care professionals. We hope that it will become a primary resource for patients and physicians to help gain an understanding of the burden of allergic rhinitis.”

The two-part Allergies in America survey reported that adult and child nasal allergy sufferers alike endure bothersome symptoms that adversely impact quality of life — from tiredness2A,3A to loss of productivity at work3B and school.2B The data also suggested that new treatment options may be warranted as both adults and children seek relief from these symptoms. Specifically, the survey reported that adult and child nasal allergy sufferers are likely to change medications that are not perceived to provide them with relief, 2C,3C and that health care practitioners overestimate patient satisfaction with their current treatment.

“The Allergies in America surveys have become critical references for understanding the magnitude of nasal disease among adults, adolescents and children, and the findings have been eye-opening,” said Eli Meltzer, M.D., Allergy and Asthma Medical Group and Research Center, San Diego. “For instance, the just-released pediatric survey that interviewed parents of children with nasal allergies, offered the first data quantifying the scope of how nasal allergy symptoms often affect children similarly to adults – from interfering with sleep and making them feel tired to impacting their general activities and reducing their school productivity. These data are important information for health care practitioners to know and be able to act upon so as to help these patients.”

About Allergies in America

The Allergies in America survey is a two-part survey conducted in individuals with nasal allergies four years of age and older that assessed the incidence, prevalence, daily life impact and treatment gaps that currently exist for patients with nasal allergies. It is the largest and most comprehensive national survey of patient and health provider perspectives concerning allergic rhinitis ever conducted.2D,3D

The first survey was conducted in adults 18 years and older. More than 31,000 households in the U.S. were screened to identify nasal allergy sufferers. Of these households, a sample of 2,500 adults, aged 18 and older, who had been diagnosed with nasal allergies and who had nasal allergy symptoms or had taken prescription medicine for their allergies in the past 12 months, were identified. These individuals were interviewed by telephone about their condition and treatment.3D A pediatric survey followed a similar design but was conducted with parents of nasal allergy sufferers under the age of 18. In the pediatric survey, more than 35,000 households in the U.S. were screened to identify nasal allergy sufferers between ages 4 and 17 to identify a national probability sample of 500 adults, aged 18 and older, who had a child who had been diagnosed with nasal allergies, and who had nasal allergy symptoms or had taken prescription medicine for their allergies in the past 12 months.2D

In addition, the survey assessed the perception of various health care professionals to determine their views on the treatment and education gaps that currently exist in nasal allergy management. The survey was conducted by the national public opinion research organization, Schulman, Ronca and Bucuvalas, Inc. (SRBI) and made public by Sepracor Inc., a manufacturer and distributor of respiratory pharmaceutical products,2E,3E and Nycomed, GmbH, a European pharmaceutical company.

About Sepracor

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor’s drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol tartrate Inhalation Aerosol, BROVANA® brand arformoterol tartrate Inhalation Solution and most recently, OMNARISTM brand ciclesonide Nasal Spray. Sepracor’s corporate headquarters are located in Marlborough, Massachusetts.

1 American Academy of Allergy, Asthma and Immunology (AAAAI). [Internet]. The Allergy Report. Available from: http://www.aaaai.org/ar/default.stm. Accessed: Feb. 18, 2008. Volume 1. Page 1

2A Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Pediatric Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2007, p. 14

2B Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Pediatric Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2007, p. 16

2C Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Pediatric Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2007, p. 24

2D,2E Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Pediatric Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2007, p. 2

3A Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2006, p. 11

3B Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2006, p. 13

3C Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2006, p. 22

3D,3E Schulman, Ronca and Bucuvalas, Inc. (SRBI). “Allergies in America: A Landmark Survey of Nasal Allergy Sufferers,” 2006, p. 2

Lunesta, Xopenex, Xopenex HFA and Brovana are registered trademarks of Sepracor Inc. Omnaris is a trademark of Nycomed GmbH.

For a copy of this release or any recent release, visit Sepracor’s web site at www.sepracor.com.